Crane Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Crane Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.31B | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $544.10M | Feb 27, 2025 |
| FY2024 | Sep 30, 2024 | $548.30M | Feb 27, 2025 |
| FY2024 | Jun 30, 2024 | $528.60M | Feb 27, 2025 |
| FY2024 | Mar 31, 2024 | $510.20M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $484.30M | Feb 27, 2025 |
| FY2024 | Sep 30, 2023 | $473.90M | Feb 27, 2025 |
| FY2024 | Jun 30, 2023 | $452.40M | Feb 27, 2025 |
| FY2024 | Mar 31, 2023 | $451.50M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $1.78B | Feb 27, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.31B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.13B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.86B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.78B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.06B | Feb 26, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $222.50M | Feb 27, 2025 |
| FY2024 | Sep 30, 2024 | $227.00M | Feb 27, 2025 |
| FY2024 | Jun 30, 2024 | $211.50M | Feb 27, 2025 |
| FY2024 | Mar 31, 2024 | $206.80M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $183.90M | Feb 27, 2025 |
| FY2024 | Sep 30, 2023 | $190.30M | Feb 27, 2025 |
| FY2024 | Jun 30, 2023 | $186.40M | Feb 27, 2025 |
| FY2024 | Mar 31, 2023 | $190.40M | Feb 27, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $294.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $255.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $401.10M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $435.40M | Feb 26, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $424.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $86.20M | Feb 27, 2025 |
| FY2024 | Sep 30, 2024 | $99.00M | Feb 27, 2025 |
| FY2024 | Jun 30, 2024 | $89.30M | Feb 27, 2025 |
| FY2024 | Mar 31, 2024 | $81.30M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $62.40M | Feb 27, 2025 |
| FY2024 | Sep 30, 2023 | $68.60M | Feb 27, 2025 |
| FY2024 | Jun 30, 2023 | $53.30M | Feb 27, 2025 |
| FY2024 | Mar 31, 2023 | $66.10M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $5.30M | Feb 27, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $46.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $54.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $48.30M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $49.50M | Feb 26, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $512.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $500.60M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $493.50M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $467.10M | Feb 26, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.85B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.64B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.35B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.39B | Feb 26, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.06B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.64B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.36B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.90B | Feb 26, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $683.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $661.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $576.40M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $519.60M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $723.20M | Feb 26, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.22B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $960.70M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.82B | Feb 26, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $506.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $306.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $329.60M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $427.00M | Feb 26, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $247.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $248.50M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Feb 26, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Sep 30, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Jun 30, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Mar 31, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 27, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 27, 2025 |
| FY2024 | Mar 31, 2023 | 1 | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | 7 | Feb 27, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Sep 30, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Jun 30, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Mar 31, 2024 | 1 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 27, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 27, 2025 |
| FY2024 | Mar 31, 2023 | 1 | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | 7 | Feb 27, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 57.29M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 56.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 56.33M | Feb 26, 2024 |